Regenerx Biopharmaceuticals Inc RGRX
We take great care to ensure that the data presented and summarized in this overview for REGENERX BIOPHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RGRX
Top Purchases
Top Sells
About RGRX
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
Insider Transactions at RGRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2021
|
Allan L Goldstein Director |
SELL
Bona fide gift
|
Direct |
130,000
-7.94%
|
-
|
|
Jun 30
2021
|
Allan L Goldstein Director |
BUY
Open market or private purchase
|
Direct |
125,000
+7.09%
|
$0
$0.2 P/Share
|
|
Jun 30
2021
|
J J Finkelstein President and CEO |
BUY
Open market or private purchase
|
Direct |
75,000
+4.19%
|
$0
$0.2 P/Share
|
|
Jun 30
2021
|
Paolo Cavazza > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+50.0%
|
$0
$0.2 P/Share
|